Latest Catalyst Pharmaceutical Partners (CPRX) Hea
Post# of 79
Posted On: 03/13/2014 7:03:24 AM
Latest Catalyst Pharmaceutical Partners (CPRX) Headlines
Catalyst Pharmaceutical Partners to Present at the 26th Annual ROTH Conference
GlobeNewswire - Thu Mar 06, 8:23AM CST
Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), today announced that the Company will be presenting at the 26 Annual ROTH Conference, in California. Steven Miller, Ph.D., Catalyst's Chief Scientific Officer/COO, will provide an overview of the Company and its key programs on Monday, March 10 at 10:30 am PT / 1:30 pm ET. The Company's presentation materials will be available on the "Investors" section of the Company's website, www.catalystpharma.com following the presentation.
Catalyst Pharmaceutical Partners Observes Rare Disease Day Today
GlobeNewswire - Fri Feb 28, 7:03AM CST
Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), a specialty pharmaceutical company focused on developing safe and effective, approved medicines targeting orphan neuromuscular and neurological diseases, joins with the National Organization for Rare Disorders (NORD) in the observance of Rare Disease Day.
5 Stocks Ready to Skyrocket Higher
at The Street - Wed Feb 19, 1:14PM CST
These stocks are setting up to explode to the upside.
Catalyst Pharmaceutical Partners to Present at 16th Annual BIO CEO & Investor Conference
GlobeNewswire - Thu Feb 06, 7:03AM CST
Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), today announced that the Company will be presenting at the 16 Annual BIO CEO & Investor Conference, in New York. Patrick J. McEnany, Chief Executive Officer and Steven Miller, Ph.D., Chief Scientific Officer/Chief Operating Officer at Catalyst, will provide an overview of the Company and its key programs on Tuesday, February 11, at 1:00 p.m. ET. The Company's presentation materials will be available on the "Investors" section of the Company's website, www.catalystpharma.com following the presentation.
Catalyst Pharmaceutical Partners Reports Positive Cardiac Safety Results of Its Phase 3 Product, Firdapse Tablets
GlobeNewswire - Wed Jan 08, 7:03AM CST
Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), a specialty pharmaceutical company focused on developing safe and effective, approved medicines targeting orphan neuromuscular and neurological diseases, today announced positive results from a study jointly funded with, and conducted by BioMarin Pharmaceuticals (Nasdaq:BMRN) to assess the cardiac safety of Firdapse(TM) tablets (amifampridine also known as 3,4-DAP). Firdapse is approved in the E.U., where it is marketed by BioMarin. Firdapse is also currently in Phase 3 development in the U.S. for Lambert-Eaton Myasthenic Syndrome (LEMS) by Catalyst.
Catalyst Pharmaceutical Partners Reports Dismissal of Stockholder Class Action Lawsuit
GlobeNewswire - Tue Jan 07, 7:05AM CST
Catalyst Pharmaceutical Partners, Inc. (Catalyst) (Nasdaq:CPRX), a specialty pharmaceutical company focused on developing safe and effective, approved medicines targeting orphan neuromuscular and neurological diseases, today announced that on January 3, 2014, the previously reported stockholder class action lawsuit that had been filed against Catalyst and certain of its officers and directors was dismissed without prejudice. In the Court's order, the plaintiffs were granted leave to file an amended complaint within 20 days. Catalyst has no information as to whether any such amended complaint is planned by the plaintiffs. If an amended complaint is filed in the case, Catalyst intends to vigorously defend the amended lawsuit.
Catalyst Pharmaceutical Partners Reports Successful Completion of Type B Breakthrough Therapy Meeting With FDA on Firdapse Tablets Development Program
GlobeNewswire - Mon Jan 06, 7:03AM CST
First Meeting With FDA Since Receiving Breakthrough Therapy Designation for Firdapse
Pre-Market Commentary: Perrigo, Allscripts Healthcare Solutions, Catalyst Pharma Partners, and Ironwood Pharma
PR Newswire - Mon Dec 23, 7:00AM CST
Editor Note: For more information about this release, please scroll to bottom.
Glancy Binkow & Goldberg LLP Announces a December 24, 2013 Lead Plaintiff Deadline in the Class Action Lawsuit Against Catalyst Pharmaceutical Partners, Inc. -- CPRX
GlobeNewswire - Fri Dec 20, 8:30PM CST
Glancy Binkow & Goldberg LLP announces that all purchasers of the securities of Catalyst Pharmaceutical Partners, Inc. ("Catalyst" or the "Company") (Nasdaq:CPRX) between October 31, 2012 and October 18, 2013, inclusive (the "Class Period'), have until December 24, 2013, to file a motion to be appointed as lead plaintiff in the shareholder lawsuit filed in the United States District Court for the Southern District of Florida.
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Catalyst Pharmaceutical Partners, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of December 24, 2013
Business Wire - Tue Dec 17, 5:50PM CST
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of Florida on behalf of investors who purchased Catalyst Pharmaceutical Partners, Inc. ("Catalyst Pharmaceutical" or the "Company") (NasdaqCM: CPRX) common stock between October 31, 2012 and October 18, 2013.
EQUITY ALERT: Rosen Law Firm Reminds Catalyst Pharmaceutical Partners Investors of Important December 24, 2013 Deadline in Class Action -- CPRX
GlobeNewswire - Tue Dec 17, 2:14AM CST
The Rosen Law Firm, P.A. reminds Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) investors who purchased Catalyst stock during the period from October 31, 2012 to October 18, 2013, inclusive, of the important December 24, 2013 lead plaintiff deadline.
Law Offices of Howard G. Smith Announces Lead Plaintiff Deadline in the Class Action Lawsuit Against Catalyst Pharmaceutical Partners, Inc.
Business Wire - Tue Dec 10, 8:32PM CST
Law Offices of Howard G. Smith announces that investors of Catalyst Pharmaceutical Partners, Inc. ("Catalyst" or the "Company") (NASDAQ:CPRX) have until December 24, 2013, to move the Court to serve as lead plaintiff in the securities fraud class action lawsuit filed in the United States District Court for the Southern District of Florida on behalf of a class (the "Class") comprising all purchasers of Catalyst securities between October 31, 2012 and October 18, 2013, inclusive (the "Class Period").
DEADLINE ALERT: Rigrodsky & Long, P.A. Reminds Shareholders of Catalyst Pharmaceutical Partners, Inc. of Upcoming Deadline
Business Wire - Mon Dec 09, 3:21PM CST
Rigrodsky & Long, P.A.:
Law Offices of Howard G. Smith Announces Class Action Lawsuit Against Catalyst Pharmaceutical Partners, Inc.
Business Wire - Fri Dec 06, 8:32PM CST
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed in the United States District Court for the Southern District of Florida on behalf of a class (the "Class") comprising all purchasers of the securities of Catalyst Pharmaceutical Partners, Inc. ("Catalyst" or the "Company") (NASDAQ:CPRX) between October 31, 2012 and October 18, 2013, inclusive (the "Class Period").
5 Stocks Under $10 Set to Soar
at The Street - Thu Dec 05, 1:12PM CST
These under-$10 stocks look ready to trade higher from current levels.
4 Biotech Stocks Under $10 to Watch
at The Street - Wed Dec 04, 6:00AM CST
Keep these under-$10 biotech stocks on your radar.
SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Reminds Investors of Class Action Against Catalyst Pharmaceutical Partners, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of December 24, 2013 -- CPRX
GlobeNewswire - Mon Dec 02, 3:29PM CST
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of Florida on behalf of investors who purchased Catalyst Pharmaceutical Partners, Inc. ("Catalyst Pharmaceutical" or the "Company") (Nasdaq:CPRX) common stock between October 31, 2012 and October 18, 2013.
Morning Research: Allscripts Healthcare Solutions Inc., Perrigo Co., and Ironwood Pharma Inc.
PR Newswire - Mon Nov 25, 8:36AM CST
Editor Note: For more information about this release, please scroll to bottom.
Pomerantz Law Firm Has Filed a Class Action Against Catalyst Pharmaceutical Partners, Inc. and Certain Officers -- CPRX
GlobeNewswire - Fri Nov 22, 5:30PM CST
Pomerantz Grossman Hufford Dahlstrom & Gross LLP has filed a class action lawsuit against Catalyst Pharmaceutical Partners, Inc. ("Catalyst" or the "Company") (Nasdaq:CPRX) and certain of its officers. The class action, filed in United States District Court, Southern District of Florida, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired Catalyst securities between October 31, 2012 and October 18, 2013 both dates inclusive (the "Class Period"). This class action seeks to recover damages against the Company and certain of its officers and directors as a result of alleged violations of the federal securities laws pursuant to Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.
Health Care Initiatives, Clinical Data Presentations, Public Offerings, Contract Extensions and Publication of Pre-Clinical Study - Research Report on Cigna, Arena, Synta, Healthways, and Catalyst
PR Newswire - Thu Nov 21, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Cigna Corp. (NYSE: CI), Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), Synta Pharmaceuticals Corp. (NASDAQ: SNTA), Healthways Inc. (NASDAQ: HWAY), and Catalyst Pharmaceutical Partners Inc. (NASDAQ: CPRX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Catalyst Pharmaceutical Partners to Present at the 26th Annual ROTH Conference
GlobeNewswire - Thu Mar 06, 8:23AM CST
Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), today announced that the Company will be presenting at the 26 Annual ROTH Conference, in California. Steven Miller, Ph.D., Catalyst's Chief Scientific Officer/COO, will provide an overview of the Company and its key programs on Monday, March 10 at 10:30 am PT / 1:30 pm ET. The Company's presentation materials will be available on the "Investors" section of the Company's website, www.catalystpharma.com following the presentation.
Catalyst Pharmaceutical Partners Observes Rare Disease Day Today
GlobeNewswire - Fri Feb 28, 7:03AM CST
Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), a specialty pharmaceutical company focused on developing safe and effective, approved medicines targeting orphan neuromuscular and neurological diseases, joins with the National Organization for Rare Disorders (NORD) in the observance of Rare Disease Day.
5 Stocks Ready to Skyrocket Higher
at The Street - Wed Feb 19, 1:14PM CST
These stocks are setting up to explode to the upside.
Catalyst Pharmaceutical Partners to Present at 16th Annual BIO CEO & Investor Conference
GlobeNewswire - Thu Feb 06, 7:03AM CST
Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), today announced that the Company will be presenting at the 16 Annual BIO CEO & Investor Conference, in New York. Patrick J. McEnany, Chief Executive Officer and Steven Miller, Ph.D., Chief Scientific Officer/Chief Operating Officer at Catalyst, will provide an overview of the Company and its key programs on Tuesday, February 11, at 1:00 p.m. ET. The Company's presentation materials will be available on the "Investors" section of the Company's website, www.catalystpharma.com following the presentation.
Catalyst Pharmaceutical Partners Reports Positive Cardiac Safety Results of Its Phase 3 Product, Firdapse Tablets
GlobeNewswire - Wed Jan 08, 7:03AM CST
Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), a specialty pharmaceutical company focused on developing safe and effective, approved medicines targeting orphan neuromuscular and neurological diseases, today announced positive results from a study jointly funded with, and conducted by BioMarin Pharmaceuticals (Nasdaq:BMRN) to assess the cardiac safety of Firdapse(TM) tablets (amifampridine also known as 3,4-DAP). Firdapse is approved in the E.U., where it is marketed by BioMarin. Firdapse is also currently in Phase 3 development in the U.S. for Lambert-Eaton Myasthenic Syndrome (LEMS) by Catalyst.
Catalyst Pharmaceutical Partners Reports Dismissal of Stockholder Class Action Lawsuit
GlobeNewswire - Tue Jan 07, 7:05AM CST
Catalyst Pharmaceutical Partners, Inc. (Catalyst) (Nasdaq:CPRX), a specialty pharmaceutical company focused on developing safe and effective, approved medicines targeting orphan neuromuscular and neurological diseases, today announced that on January 3, 2014, the previously reported stockholder class action lawsuit that had been filed against Catalyst and certain of its officers and directors was dismissed without prejudice. In the Court's order, the plaintiffs were granted leave to file an amended complaint within 20 days. Catalyst has no information as to whether any such amended complaint is planned by the plaintiffs. If an amended complaint is filed in the case, Catalyst intends to vigorously defend the amended lawsuit.
Catalyst Pharmaceutical Partners Reports Successful Completion of Type B Breakthrough Therapy Meeting With FDA on Firdapse Tablets Development Program
GlobeNewswire - Mon Jan 06, 7:03AM CST
First Meeting With FDA Since Receiving Breakthrough Therapy Designation for Firdapse
Pre-Market Commentary: Perrigo, Allscripts Healthcare Solutions, Catalyst Pharma Partners, and Ironwood Pharma
PR Newswire - Mon Dec 23, 7:00AM CST
Editor Note: For more information about this release, please scroll to bottom.
Glancy Binkow & Goldberg LLP Announces a December 24, 2013 Lead Plaintiff Deadline in the Class Action Lawsuit Against Catalyst Pharmaceutical Partners, Inc. -- CPRX
GlobeNewswire - Fri Dec 20, 8:30PM CST
Glancy Binkow & Goldberg LLP announces that all purchasers of the securities of Catalyst Pharmaceutical Partners, Inc. ("Catalyst" or the "Company") (Nasdaq:CPRX) between October 31, 2012 and October 18, 2013, inclusive (the "Class Period'), have until December 24, 2013, to file a motion to be appointed as lead plaintiff in the shareholder lawsuit filed in the United States District Court for the Southern District of Florida.
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Catalyst Pharmaceutical Partners, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of December 24, 2013
Business Wire - Tue Dec 17, 5:50PM CST
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of Florida on behalf of investors who purchased Catalyst Pharmaceutical Partners, Inc. ("Catalyst Pharmaceutical" or the "Company") (NasdaqCM: CPRX) common stock between October 31, 2012 and October 18, 2013.
EQUITY ALERT: Rosen Law Firm Reminds Catalyst Pharmaceutical Partners Investors of Important December 24, 2013 Deadline in Class Action -- CPRX
GlobeNewswire - Tue Dec 17, 2:14AM CST
The Rosen Law Firm, P.A. reminds Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) investors who purchased Catalyst stock during the period from October 31, 2012 to October 18, 2013, inclusive, of the important December 24, 2013 lead plaintiff deadline.
Law Offices of Howard G. Smith Announces Lead Plaintiff Deadline in the Class Action Lawsuit Against Catalyst Pharmaceutical Partners, Inc.
Business Wire - Tue Dec 10, 8:32PM CST
Law Offices of Howard G. Smith announces that investors of Catalyst Pharmaceutical Partners, Inc. ("Catalyst" or the "Company") (NASDAQ:CPRX) have until December 24, 2013, to move the Court to serve as lead plaintiff in the securities fraud class action lawsuit filed in the United States District Court for the Southern District of Florida on behalf of a class (the "Class") comprising all purchasers of Catalyst securities between October 31, 2012 and October 18, 2013, inclusive (the "Class Period").
DEADLINE ALERT: Rigrodsky & Long, P.A. Reminds Shareholders of Catalyst Pharmaceutical Partners, Inc. of Upcoming Deadline
Business Wire - Mon Dec 09, 3:21PM CST
Rigrodsky & Long, P.A.:
Law Offices of Howard G. Smith Announces Class Action Lawsuit Against Catalyst Pharmaceutical Partners, Inc.
Business Wire - Fri Dec 06, 8:32PM CST
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed in the United States District Court for the Southern District of Florida on behalf of a class (the "Class") comprising all purchasers of the securities of Catalyst Pharmaceutical Partners, Inc. ("Catalyst" or the "Company") (NASDAQ:CPRX) between October 31, 2012 and October 18, 2013, inclusive (the "Class Period").
5 Stocks Under $10 Set to Soar
at The Street - Thu Dec 05, 1:12PM CST
These under-$10 stocks look ready to trade higher from current levels.
4 Biotech Stocks Under $10 to Watch
at The Street - Wed Dec 04, 6:00AM CST
Keep these under-$10 biotech stocks on your radar.
SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Reminds Investors of Class Action Against Catalyst Pharmaceutical Partners, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of December 24, 2013 -- CPRX
GlobeNewswire - Mon Dec 02, 3:29PM CST
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of Florida on behalf of investors who purchased Catalyst Pharmaceutical Partners, Inc. ("Catalyst Pharmaceutical" or the "Company") (Nasdaq:CPRX) common stock between October 31, 2012 and October 18, 2013.
Morning Research: Allscripts Healthcare Solutions Inc., Perrigo Co., and Ironwood Pharma Inc.
PR Newswire - Mon Nov 25, 8:36AM CST
Editor Note: For more information about this release, please scroll to bottom.
Pomerantz Law Firm Has Filed a Class Action Against Catalyst Pharmaceutical Partners, Inc. and Certain Officers -- CPRX
GlobeNewswire - Fri Nov 22, 5:30PM CST
Pomerantz Grossman Hufford Dahlstrom & Gross LLP has filed a class action lawsuit against Catalyst Pharmaceutical Partners, Inc. ("Catalyst" or the "Company") (Nasdaq:CPRX) and certain of its officers. The class action, filed in United States District Court, Southern District of Florida, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired Catalyst securities between October 31, 2012 and October 18, 2013 both dates inclusive (the "Class Period"). This class action seeks to recover damages against the Company and certain of its officers and directors as a result of alleged violations of the federal securities laws pursuant to Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.
Health Care Initiatives, Clinical Data Presentations, Public Offerings, Contract Extensions and Publication of Pre-Clinical Study - Research Report on Cigna, Arena, Synta, Healthways, and Catalyst
PR Newswire - Thu Nov 21, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Cigna Corp. (NYSE: CI), Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), Synta Pharmaceuticals Corp. (NASDAQ: SNTA), Healthways Inc. (NASDAQ: HWAY), and Catalyst Pharmaceutical Partners Inc. (NASDAQ: CPRX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
(0)
(0)Catalyst Pharmaceuticals Inc. (CPRX) Stock Research Links
Scroll down for more posts ▼